H E Bays

Summary

Publications

  1. ncbi Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY 40213, USA
    J Clin Lipidol 6:565-72. 2012
  2. ncbi Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Avenue, Louisville, KY, 40213, USA
    Am J Cardiovasc Drugs 13:37-46. 2013
  3. ncbi Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating "sick fat" through improving fat function with antidiabetes therapies
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, USA
    Am J Cardiol 110:4B-12B. 2012
  4. ncbi Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY 40213, USA
    Int J Cardiol 153:141-7. 2011
  5. ncbi Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups
    Harold E Bays
    L MARC Research Center, Louisville, KY 40213, USA
    Am J Cardiovasc Drugs 12:197-206. 2012
  6. ncbi Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity
    H E Bays
    L MARC Research Center, Louisville, Kentucky 40213, USA
    Drugs Today (Barc) 47:903-14. 2011
  7. ncbi Colesevelam hydrochloride added to background metformin therapy in patients with type 2 diabetes mellitus: a pooled analysis from 3 clinical studies
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Inc, Louisville, Kentucky 40213, USA
    Endocr Pract 17:933-8. 2011
  8. ncbi Reduced viscosity Barley β-Glucan versus placebo: a randomized controlled trial of the effects on insulin sensitivity for individuals at risk for diabetes mellitus
    Harold Bays
    Frestedt Incorporated, 2708 Vernon Avenue South, Minneapolis, 55416, USA
    Nutr Metab (Lond) 8:58. 2011
  9. ncbi Ezetimibe: cholesterol lowering and beyond
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA
    Expert Rev Cardiovasc Ther 6:447-70. 2008
  10. ncbi Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians
    Harold Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY 40213, USA
    Drugs Today (Barc) 44:205-46. 2008

Detail Information

Publications86

  1. ncbi Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY 40213, USA
    J Clin Lipidol 6:565-72. 2012
    ....
  2. ncbi Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Avenue, Louisville, KY, 40213, USA
    Am J Cardiovasc Drugs 13:37-46. 2013
    ..This analysis examined the effect of IPE on inflammatory markers in patients from MARINE and ANCHOR...
  3. ncbi Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating "sick fat" through improving fat function with antidiabetes therapies
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, USA
    Am J Cardiol 110:4B-12B. 2012
    ....
  4. ncbi Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY 40213, USA
    Int J Cardiol 153:141-7. 2011
    ..Age, gender, and race are factors that influence atherosclerotic coronary heart disease (CHD) risk and may conceivably affect the efficacy of lipid-altering drugs...
  5. ncbi Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups
    Harold E Bays
    L MARC Research Center, Louisville, KY 40213, USA
    Am J Cardiovasc Drugs 12:197-206. 2012
    ....
  6. ncbi Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity
    H E Bays
    L MARC Research Center, Louisville, Kentucky 40213, USA
    Drugs Today (Barc) 47:903-14. 2011
    ..Reported adverse events with this combination agent are as expected, based upon knowledge of the individual components...
  7. ncbi Colesevelam hydrochloride added to background metformin therapy in patients with type 2 diabetes mellitus: a pooled analysis from 3 clinical studies
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Inc, Louisville, Kentucky 40213, USA
    Endocr Pract 17:933-8. 2011
    ..To evaluate the glucose- and lipid-altering efficacy of colesevelam hydrochloride (HCl) when added to background metformin therapy in patients with inadequately controlled type 2 diabetes mellitus (T2DM)...
  8. ncbi Reduced viscosity Barley β-Glucan versus placebo: a randomized controlled trial of the effects on insulin sensitivity for individuals at risk for diabetes mellitus
    Harold Bays
    Frestedt Incorporated, 2708 Vernon Avenue South, Minneapolis, 55416, USA
    Nutr Metab (Lond) 8:58. 2011
    ..abstract:..
  9. ncbi Ezetimibe: cholesterol lowering and beyond
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA
    Expert Rev Cardiovasc Ther 6:447-70. 2008
    ..The clinical significance of the LDL-cholesterol lowering and other effects of ezetimibe is being evaluated in clinical outcome studies...
  10. ncbi Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians
    Harold Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY 40213, USA
    Drugs Today (Barc) 44:205-46. 2008
    ..Finally, this review examines P-OM3's lipid and cardiovascular effects, safety, and tolerability, as well as its practical role in patient management...
  11. ncbi The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, USA
    Diabetes Care 33:2113-6. 2010
    ..To compare fenofibric acid (FA) + statin to respective monotherapies on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia...
  12. ncbi Is adiposopathy (sick fat) an endocrine disease?
    H E Bays
    L MARC Research Center, Louisville, KY 40213, USA
    Int J Clin Pract 62:1474-83. 2008
    ....
  13. ncbi Safety of niacin and simvastatin combination therapy
    Harold Bays
    L MARC Research Center, Louisville, Kentucky 40213, USA
    Am J Cardiol 101:3B-8B. 2008
    ..Equally important is ensuring that the combination of niacin and simvastatin has an acceptable safety profile, with no greater AEs than would otherwise be expected by adding 1 agent to the other...
  14. ncbi Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease
    Harold Bays
    L MARC Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA
    Expert Rev Cardiovasc Ther 8:1777-801. 2010
    ....
  15. ncbi Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA
    Expert Rev Cardiovasc Ther 6:391-409. 2008
    ....
  16. ncbi Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity
    Harold E Bays
    L MARC Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA
    Expert Rev Cardiovasc Ther 6:343-68. 2008
    ....
  17. ncbi Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups
    H Bays
    L MARC Research Center, Louisville, KY 40213, USA
    Int J Clin Pract 65:436-45. 2011
    ..In patients with primary hypercholesterolemia or mixed dyslipidemia, extended-release niacin/laropiprant (ERN/LRPT) improves key lipid parameters associated with increased atherosclerotic coronary heart disease (CHD) risk...
  18. ncbi The 'forgotten' bile acid sequestrants: is now a good time to remember?
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY 40213, USA
    Am J Ther 14:567-80. 2007
    ....
  19. ncbi Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors
    Harold Bays
    L MARC Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA
    Vasc Health Risk Manag 3:733-42. 2007
    ..Finally this paper specifically reviews colesevelam HCl's pharmacology, lipid and glucose efficacy, safety/tolerability, and clinical use...
  20. ncbi Prevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the US population: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes)
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA
    BMC Public Health 7:277. 2007
    ....
  21. ncbi Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia
    Harold Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY 40213, USA
    Curr Med Res Opin 24:2953-66. 2008
    ..This study evaluated the long-term safety and tolerability of ezetimibe/simvastatin coadministration therapy compared to simvastatin monotherapy in patients with primary hypercholesterolemia...
  22. ncbi Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center Inc, 3288 Illinois Ave, Louisville, KY 40213, USA
    Arch Intern Med 168:1975-83. 2008
    ..Bile acid sequestrants are a well-accepted class of cholesterol-lowering drugs. Over the last decade, small studies have indicated that these agents may also lower glucose levels in patients with type 2 diabetes mellitus (T2DM)...
  23. ncbi Does nicotinic acid (niacin) lower blood pressure?
    H E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY40213, USA
    Int J Clin Pract 63:151-9. 2009
    ..Further research is warranted to evaluate the extent and mechanisms of niacin's effects on BP...
  24. ncbi Anthropometric measurements and diabetes mellitus: clues to the "pathogenic" and "protective" potential of adipose tissue
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky 40213, USA
    Metab Syndr Relat Disord 8:307-15. 2010
    ..Increased subcutaneous adipose tissue (SAT) is often described as "protective" against metabolic disease and frequently approximated by hip circumference (HC)...
  25. ncbi Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY 40213, USA
    Curr Med Res Opin 26:907-15. 2010
    ..Assess the long-term efficacy and safety of prescription omega-3-acid ethyl esters (P-OM3) coadministered with simvastatin in an extension of the Combination of Prescription Omega-3 Plus Simvastatin (COMBOS) trial...
  26. ncbi Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Ave, Louisville, KY 40213, USA
    Mayo Clin Proc 85:122-8. 2010
    ..To evaluate the effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol (HDL-C) levels in atorvastatin-treated patients with elevated non-HDL-C and triglyceride levels...
  27. ncbi Perceived body image in men and women with type 2 diabetes mellitus: correlation of body mass index with the figure rating scale
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA
    Nutr J 8:57. 2009
    ..This study examined the self-perception of body image to various levels of BMI among those with T2DM...
  28. ncbi Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Avenue, Louisville KY 40213, USA
    Expert Rev Cardiovasc Ther 7:1429-45. 2009
    ....
  29. ncbi The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY 40213, USA
    Postgrad Med 121:145-50. 2009
    ..Thus, the 4-g/day dose contributes approximately 44 Cal/day, with approximately 36 Cal/day derived from the oil...
  30. ncbi Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia
    Harold Bays
    L MARC Research Center, Louisville KY, USA
    Future Cardiol 1:39-59. 2005
    ..It is hoped that these obstacles can, to some extent, be addressed and overcome by clearly defining and increasing our understanding of adiposopathy...
  31. ncbi What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?
    Harold E Bays
    L MARC Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA
    Curr Opin Lipidol 20:467-76. 2009
    ..The most commonly reported reason for the lack of its more widespread clinical use is niacin-induced flushing...
  32. ncbi Adiposopathy and bariatric surgery: is 'sick fat' a surgical disease?
    H E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY 40213, USA
    Int J Clin Pract 63:1285-300. 2009
    ....
  33. ncbi Review of ARBITER 2: Extended-Release Niacin Added to Statin Therapy Slows the Progression of Atherosclerosis
    Harold Bays
    Louisville Metabolic and Atherosclerotic Research Center, Louisville, KY, 40213, USA
    Postgrad Med 121:195-8. 2009
    ..However, prior to 2004, limited data documented the carotid atherosclerotic lesion benefits of niacin when added to statin therapy...
  34. ncbi From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus
    Harold Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY 40213, USA
    Curr Med Res Opin 25:671-81. 2009
    ..This supports the need for additional strategies for the treatment of hyperglycaemia...
  35. ncbi "Sick fat," metabolic disease, and atherosclerosis
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center L MARC, Louisville, Kentucky 40213, USA
    Am J Med 122:S26-37. 2009
    ....
  36. ncbi A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus
    Harold Bays
    Louisville Metabolic and Atherosclerosis Research Center Inc L MARC, 3288 Illinois Avenue, Louisville, KY 40213, USA
    Diab Vasc Dis Res 4:181-93. 2007
    ..In summary, tesaglitazar provided similar glycaemic control to pioglitazone, was associated with significant improvement in lipid and lipoprotein variables, and increased serum creatinine in a dose-dependent manner...
  37. ncbi Colesevelam hydrochloride powder for oral suspension versus cholestyramine powder for oral suspension: comparison of acceptability and tolerability
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, USA
    Endocr Pract 17:218-25. 2011
    ..To compare tolerability of colesevelam hydrochloride powder versus a cholesterol-lowering equivalent dose of generic cholestyramine powder, each mixed in water, by means of the validated Bile Acid Sequestrant Acceptability (BASA) Scale...
  38. ncbi Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY 40213, USA
    Prev Cardiol 8:226-33. 2005
    ..These time differences may have potential clinical relevance in reducing coronary heart disease risk...
  39. ncbi Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Kentucky, USA
    Am J Cardiol 108:682-90. 2011
    ....
  40. ncbi Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything
    Harold Bays
    L MARC Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA
    Expert Rev Cardiovasc Ther 3:393-404. 2005
    ..Adiposopathy is a plausible Theory of Everything for mankind's greatest metabolic epidemics...
  41. ncbi MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin
    Harold E Bays
    L MARC Research Center, Louisville, Kentucky 40213, USA
    J Clin Endocrinol Metab 96:2889-97. 2011
    ....
  42. ncbi A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA
    Clin Ther 26:1758-73. 2004
    ....
  43. ncbi Current and investigational antiobesity agents and obesity therapeutic treatment targets
    Harold E Bays
    FACP Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Ave, Louisville, KY 40213, USA
    Obes Res 12:1197-211. 2004
    ..Finally, an emerging concept is that the development of antiobesity agents must not only reduce fat mass (adiposity) but must also correct fat dysfunction (adiposopathy)...
  44. ncbi Extended-release niacin/lovastatin: the first combination product for dyslipidemia
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA
    Expert Rev Cardiovasc Ther 2:485-501. 2004
    ..This review summarizes the efficacy and safety of extended-release niacin/lovastatin (Advicor, Kos Pharmaceuticals Inc.), the first combination product approved for the management of dyslipidemia...
  45. ncbi Adiposopathy is "sick fat" a cardiovascular disease?
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, USA
    J Am Coll Cardiol 57:2461-73. 2011
    ..Finally, this review describes how "sick fat" helps account for various clinical obesity/cardiovascular paradoxes, supporting adiposopathy as a cardiovascular disease...
  46. ncbi Pharmacotherapy for dyslipidaemia--current therapies and future agents
    Harold Bays
    L MARC Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA
    Expert Opin Pharmacother 4:1901-38. 2003
    ..Finally, current and future lipid-altering drugs may include anti-obesity agents which could favourably affect lipid levels...
  47. ncbi Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky 40213, USA
    Am J Cardiol 92:538-43. 2003
    ..At the higher doses, gemcabene significantly reduced LDL cholesterol levels in all patients with low HDL cholesterol...
  48. ncbi The Bile Acid Sequestrant Acceptability scale validation study
    H E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA
    Int J Clin Pract 64:1393-7. 2010
    ..A secondary objective was to assess the utility of weightings based on subjective clinical importance for the BASA scale individual components and its composite score...
  49. ncbi Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study)
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, USA
    Am J Cardiol 108:523-30. 2011
    ....
  50. ncbi Statin safety: an overview and assessment of the data--2005
    Harold Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky 40213, USA
    Am J Cardiol 97:6C-26C. 2006
    ..This review presents an assessment of statin safety based on an overview of the current statin safety data and their clinical implications...
  51. ncbi Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center Incorporated, Louisville, Kentucky, USA
    Am J Cardiol 97:1198-205. 2006
    ..0069). In conclusion, this is the first report suggesting that an approved cholesterol-lowering bile acid sequestrant, specifically colesevelam HCl, decreases hs-CRP levels when added to statin therapy...
  52. ncbi Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome
    Harold E Bays
    L MARC Research Center, Louisville, Kentucky, USA
    Metab Syndr Relat Disord 9:135-42. 2011
    ..The objective of this investigation was to compare the treatment response of ezetimibe co-administered with fenofibrate in mixed dyslipidemic patients with and without metabolic syndrome...
  53. ncbi Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center Inc, Louisville, KY 40213, USA
    Curr Med Res Opin 23:1673-84. 2007
    ..Unfortunately, many patients with T2DM do not achieve either lipid or glucose treatment targets...
  54. ncbi The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys
    H E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY 40213, USA
    Int J Clin Pract 61:737-47. 2007
    ..Except for dyslipidaemia prevalence, SHIELD was comparable with NHANES. Consumer panel surveys may be an alternative method to collect data on the relationship of BMI and metabolic diseases...
  55. ncbi Safety considerations with omega-3 fatty acid therapy
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky 40213, USA
    Am J Cardiol 99:35C-43C. 2007
    ....
  56. ncbi Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?
    Harold Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA
    Lipids Health Dis 9:136. 2010
    ....
  57. ncbi Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY 40213, USA
    J Clin Lipidol 4:515-21. 2010
    ..Laropiprant (LRPT) reduces niacin-induced flushing and, in combination with extended-release niacin (ERN/LRPT), improves lipid levels...
  58. ncbi Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?
    Harold Bays
    L MARC Research Center, Medical Director President, 3288 Illinois Avenue, Louisville, KY 40213, USA
    Expert Rev Cardiovasc Ther 4:871-95. 2006
    ..This review describes how adiposopathy interventions may affect fat function, and thus improve EFRMD...
  59. ncbi Lipid-lowering effects of colesevelam HCl in combination with ezetimibe
    Harold Bays
    Louisville Metabolic and Atherosclerosis Research Center Inc, Louisville, KY 40213, USA
    Curr Med Res Opin 22:2191-200. 2006
    ..The primary aim of this study was to compare the effect of colesevelam HCl in combination with ezetimibe to ezetimibe monotherapy on low-density lipoprotein cholesterol (LDL-C) levels in subjects with primary hypercholesterolemia...
  60. ncbi The melanocortin system as a therapeutic treatment target for adiposity and adiposopathy
    Harold Bays
    L MARC Research Center, Louisville, Kentucky 40213, USA
    Drugs R D 7:289-302. 2006
    ....
  61. ncbi Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids
    Harold Bays
    L MARC Research Center, Louisville, Kentucky 40213, USA
    Am J Cardiol 98:71i-76i. 2006
    ..Omacor provides a safe, effective, well-tolerated approach to management of hypertriglyceridemia...
  62. ncbi Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY 40213, USA
    Expert Rev Cardiovasc Ther 9:265-77. 2011
    ..This article profiles lorcaserin as an illustrative example of general drug development regulatory processes, and specifically details the unique challenge of weight-loss drug development...
  63. ncbi Adiposopathy is a more rational treatment target for metabolic disease than obesity alone
    Harold Bays
    L MARC Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA
    Curr Atheroscler Rep 8:144-56. 2006
    ..Cannabinoid receptor antagonists and peroxisome proliferator activated receptor agonists are examples of agents that physiologically improve fat function and clinically improve metabolic disease...
  64. ncbi Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE])
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky 40213, USA
    Am J Cardiol 91:667-72. 2003
    ....
  65. ncbi Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients
    Harold E Bays
    L-MARC Research Center, Louisville, Kentucky, USA
    Am J Cardiol 90:942-6. 2002
    ..Simvastatin had no effect on VCAM, SAA, or IL-6. In summary, simvastatin significantly reduced CRP in patients with mixed hyperlipidemia and hypertriglyceridemia...
  66. ncbi Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY 40213, USA
    Prev Cardiol 6:179-88. 2003
    ....
  67. ncbi Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center Inc, Louisville, Kentucky, USA
    Clin Ther 31:115-22. 2009
    ..While the lipid effects of ERN are well known, the blood pressure effects are unclear...
  68. ncbi Comparison of self-reported survey (SHIELD) versus NHANES data in estimating prevalence of dyslipidemia
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA
    Curr Med Res Opin 24:1179-86. 2008
    ....
  69. ncbi Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies
    H E Bays
    Louisville Metabolic and Atherosclerosis Research Center Louisville, Kentucky, USA
    Clin Ther 23:1209-30. 2001
    ..Conclusions: In these two 12-week studies, ezetimibe significantly decreased plasma LDL-C levels and increased plasma HDL-C levels, with a tolerability profile similar to that of placebo...
  70. ncbi Chitin-glucan fiber effects on oxidized low-density lipoprotein: a randomized controlled trial
    H E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA
    Eur J Clin Nutr 67:2-7. 2013
    ....
  71. ncbi Metabolic syndrome: what might be occurring?
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA
    Manag Care 13:13-6. 2004
  72. ncbi Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study
    Michael H Davidson
    Radiant Research, 515 North State Street, Suite 2700, Chicago, IL 60610, USA
    Clin Ther 29:1354-67. 2007
    ..The National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) has identified non-HDL-C as a secondary therapeutic target in these patients, but treatment goals may not be reached with statin monotherapy alone...
  73. ncbi Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia
    Claude Gagne
    CHUL du CHUQ, Ste Foy, Quebec, Canada
    Am J Cardiol 90:1084-91. 2002
    ..Ezetimibe offers a new therapeutic option for patients receiving statins who require further reduction in LDL cholesterol...
  74. ncbi Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial
    W Virgil Brown
    Emory University School of Medicine, Atlanta, GA 30322, USA
    Am Heart J 144:1036-43. 2002
    ..The primary objective of this trial was to compare the efficacy of rosuvastatin with that of pravastatin and simvastatin for lowering low-density lipoprotein cholesterol (LDL-C) levels...
  75. ncbi Results of two clinical trials on the safety and efficacy of pravastatin 80 and 160 mg per day
    Robert S Rosenson
    Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Am J Cardiol 91:878-81. 2003
  76. ncbi Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)
    Peter H Jones
    Baylor College of Medicine, 6565 Fannin Avenue, A 601, Houston, TX 77030, USA
    Am J Cardiol 92:152-60. 2003
    ..0 mmol/L was achieved by 79% to 92% in rosuvastatin groups compared with 52% to 81% in atorvastatin groups. Drug tolerability was similar across treatments...
  77. ncbi Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia
    Donald B Hunninghake
    Heart Disease Prevention Clinic, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Coron Artery Dis 15:115-23. 2004
    ..We examined the effects of rosuvastatin treatment on triglyceride levels and lipid measures in a parallel-group multicenter trial (4522IL/0035) in patients with hypertriglyceridemia (Fredrickson Type IIb or IV)...
  78. ncbi Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome
    Prakash C Deedwania
    VA Central California Health Care System and University of California-San Francisco, Fresno, California, USA
    Am J Cardiol 95:360-6. 2005
    ..Rosuvastatin had the most favorable effect on the atherogenic lipid profile of MS overall...
  79. ncbi Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin
    James M McKenney
    National Clinical Research Inc, 2809 Emerywood Parkway, Ste 140, Richmond, VA 23294, USA
    J Cardiovasc Pharmacol 46:594-9. 2005
    ..Selecting the starting dose of atorvastatin using a treatment algorithm achieves NCEP ATP III LDL-cholesterol goals in the majority of patients and minimizes the need for dose titration...
  80. ncbi Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia
    John F Paolini
    Merck Research Laboratories, Rahway, NJ, USA
    Am J Cardiol 101:625-30. 2008
    ..LRPT plus ERN was well tolerated. In conclusion, the significant reduction in ERN-induced flushing provided by LRPT plus ERN supports an accelerated ERN dose-advancement paradigm to achieve rapidly a 2-g dose in dyslipidemic patients...
  81. ncbi Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia
    James M McKenney
    National Clinical Research Inc, Richmond, Virginia 23294, USA
    J Am Coll Cardiol 47:1584-7. 2006
    ..This study sought to determine the long-term safety and efficacy of co-administered fenofibrate (FENO) and ezetimibe (EZE) in patients with mixed hyperlipidemia...
  82. ncbi Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects
    Michael H Davidson
    Department of Cardiology, Rush University Medical College, 60610, USA
    Clin Cardiol 29:268-73. 2006
    ....
  83. ncbi Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)
    James M McKenney
    National Clinical Research, Richmond, VA 23227, United States
    Atherosclerosis 192:432-7. 2007
    ..No drug-related myopathy or hepatotoxicity was observed. In this study, low to moderate dose combination therapy with a statin and niacin ER provided broad control of lipids and lipoproteins independently associated with CHD...
  84. ncbi Safety considerations with niacin therapy
    John R Guyton
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Cardiol 99:22C-31C. 2007
    ..Overall, the perception of niacin side effects is often greater than the reality. As a result, a valuable medication for cardiovascular risk is underused...
  85. ncbi Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective
    Kathleen M Fox
    University of Maryland School of Medicine, Department of Epidemiology and Preventive Medicine, Baltimore, MD, USA
    Curr Med Res Opin 23:2125-33. 2007
    ..To compare effectiveness of rosuvastatin (RSV) with other statins on lowering low-density lipoprotein cholesterol (LDL-C) and LDL-C goal attainment among patients with type 1 or type 2 diabetes mellitus...
  86. ncbi Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia
    Moti L Kashyap
    Veterans Affairs Healthcare System, Long Beach, California 90822, USA
    Am J Cardiol 89:672-8. 2002
    ..5%. Once-daily niacin/lovastatin exhibits substantial effects on multiple lipid risk factors and represents a significant new treatment option in the management of dyslipidemia...